Indalpine

Indalpine Overview

Indalpine (chemically designated as 4-[2-(1H-indol-3-yl)ethyl]piperidine) is a synthetic organic compound belonging to the class of 3-alkylindoles. Structurally, it features an indole core carrying an alkyl chain substituted with a piperidine ring at the 3-position. Developed in the late 1970s and early 1980s by Pharmuka, Indalpine holds historical significance as one of the earliest selective serotonin reuptake inhibitors (SSRIs) introduced into clinical psychiatry, predating fluoxetine in several markets.

In clinical neuropsychopharmacology, Indalpine was originally introduced under the trade name Upstène for the treatment of major depressive disorder and related affective conditions. By selectively blocking presynaptic serotonin reuptake without significantly affecting norepinephrine or dopamine transporters, it represented a major structural and pharmacological advancement over tricyclic antidepressants (TCAs). However, post-marketing surveillance revealed serious safety hazards, particularly severe hematological toxicity including agranulocytosis and bone marrow suppression. Consequently, Indalpine was abruptly withdrawn from the market and discontinued worldwide.

What Is Indalpine and How Does It Work?

Indalpine is a small molecule indolyl-piperidine derivative that acts as a potent, selective inhibitor of the human sodium-dependent serotonin transporter (SERT).

Its primary pharmacological mechanisms include:

• Selective Serotonin Reuptake Inhibition: Indalpine binds with high affinity to the presynaptic sodium-dependent serotonin transporter (SERT) encoded by the SLC6A4 gene. By blocking SERT, it prevents the reuptake of serotonin (5-HT) from the synaptic cleft back into presynaptic serotonergic neurons.
• Potentiation of Serotonergic Transmission: The inhibition of SERT leads to a sustained elevation of extracellular serotonin concentrations in key brain regions regulating mood, such as the prefrontal cortex and limbic system, producing antidepressant effects.
• Selectivity Over Monoamine Transporters: Unlike classic tricyclic antidepressants, Indalpine displays minimal affinity for norepinephrine or dopamine transporters, as well as reduced binding to histaminic, muscarinic, and alpha-adrenergic receptors, minimizing anticholinergic and sedative side effects.
• Cytochrome P450 Inhibition: Indalpine functions as both a substrate and moderate inhibitor of Cytochrome P450 3A4 (CYP3A4) enzymes.

Is Indalpine FDA Approved?

No, Indalpine was never approved by the US FDA for clinical prescription or commercial distribution in the United States. First introduced for medical use internationally in France in 1983 under the trade name Upstène, it was one of the earliest selective serotonin reuptake inhibitors (SSRIs) brought to market. However, following post-marketing surveillance linking the drug to severe, unpredictable hematological toxicity including agranulocytosis and bone marrow depression Indalpine was permanently withdrawn and discontinued worldwide in 1985.

What Was Indalpine Used For?

• Historical treatment of major depressive disorder (MDD) and severe depressive episodes.
• Historical treatment of anxiety disorders and dysthymia associated with serotonergic dysregulation.

Before Taking Indalpine: Contraindications & Precautions

Strictly contraindicated in individuals with a history of bone marrow depression, blood dyscrasias, drug-induced agranulocytosis, or severe hepatic impairment. Do not use concurrently with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI due to the fatal risk of serotonin syndrome. Indalpine was permanently withdrawn worldwide in 1985 due to severe hematological toxicity (agranulocytosis and bone marrow suppression) and was never approved by the US FDA. Use during pregnancy and lactation is strictly contraindicated due to potential bone marrow toxicity and fetal serotonergic risks.

Who Should Not Take Indalpine?

• Individuals with a history of bone marrow depression, blood dyscrasias, or drug-induced agranulocytosis.
• Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI, due to the extreme risk of fatal serotonin syndrome.
• Individuals with a documented hypersensitivity to Indalpine, 3-alkylindoles, or formulation excipients.
• Patients with severe hepatic impairment or active liver disease.

Indalpine, Pregnancy & Fertility

Systemic drug exposure occurs readily following oral administration. Adequate clinical reproductive safety studies in pregnant women are lacking. Because Indalpine is associated with bone marrow suppression and serotonergic toxicity, it is strictly contraindicated during pregnancy and breastfeeding.

Tell Your Doctor Before Taking Indalpine

Because Indalpine has been withdrawn from global markets due to severe blood dyscrasias, it should never be taken. Patients evaluating depression treatments should discuss safe, modern FDA-approved antidepressants with their healthcare provider.

Indalpine Dosage & Administration

Indalpine (Upstène) is a withdrawn medication with no approved clinical indications, making standard therapeutic dosing guidelines obsolete. Formulated historically for oral administration in tablet or capsule form. Historical therapeutic regimens for major depressive disorder involved daily doses divided into 2 to 3 administrations. It is no longer manufactured or available for legal medical administration under any circumstances.

Standard Indalpine Dosing

• Standardized modern clinical dosing guidelines are obsolete because Indalpine has been withdrawn from clinical practice. Historical oral therapeutic regimens typically utilized daily doses divided into 2 to 3 administrations.

How Indalpine Was Administered

• Historically administered via the oral route in tablet or capsule form.

Indalpine Clinical Efficacy & Research

Early clinical trials in the late 1970s and early 1980s demonstrated that Indalpine was an effective antidepressant, producing significant clinical reductions in Hamilton Depression Rating Scale (HDRS) scores comparable to tricyclic antidepressants like imipramine and amitriptyline. Patients experienced far fewer anticholinergic side effects (such as dry mouth, blurred vision, and urinary retention). However, post-marketing safety monitoring revealed cases of severe, unpredictable neutropenia and agranulocytosis, leading regulatory health authorities to revoke its authorizations.

Indalpine Side Effects & Safety Profile

Common historical side effects included gastrointestinal distress (nausea, diarrhea), insomnia, mild agitation, restlessness, headache, dizziness, tremors, and excessive sweating. Serious adverse risks included severe agranulocytosis and bone marrow suppression (precipitous drops in absolute neutrophil count leading to opportunistic infections and sepsis), life-threatening serotonin syndrome, and moderate CYP3A4 inhibition. Holds no modern US FDA Black Box Warning due to its unapproved regulatory status in North America, though classical warnings emphasize critical hazards regarding severe neutropenia, serotonin syndrome, and suicidality.

Common Indalpine Side Effects

• Nausea, gastrointestinal distress, and diarrhea.
• Insomnia, mild agitation, or restlessness.
• Headache, dizziness, and mild tremors.
• Excessive sweating (diaphoresis).

Serious Indalpine Adverse Events

• Agranulocytosis & Bone Marrow Suppression: Severe, potentially fatal drops in absolute neutrophil counts, leading to severe opportunistic infections and sepsis.
• Serotonin Syndrome: High fever, autonomic instability, hyperreflexia, clonus, confusion, and potential coma when combined with other serotonergic agents.
• Moderate CYP3A4 Inhibition: Alterations in hepatic clearance of co-administered prescription medications.

Managing Indalpine Side Effects

Immediate cessation of Indalpine is mandatory if any adverse reaction occurs. Patients exhibiting fever, sore throat, or signs of infection require an immediate complete blood count (CBC) to rule out agranulocytosis.

Indalpine Drug Interactions & What to Avoid

Co-administration with MAOIs is strictly contraindicated due to the extreme risk of fatal serotonin syndrome. Combining with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, St. John’s Wort) significantly increases serotonin toxicity risks. As a moderate CYP3A4 inhibitor, Indalpine can elevate plasma concentrations of co-administered CYP3A4 substrates. Alcohol must be strictly avoided due to additive central nervous system depression.

Indalpine Drug-Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs): Severe, life-threatening risk of Serotonin Syndrome. Co-administration is strictly contraindicated.
• Other Serotonergic Drugs (SSRIs, SNRIs, Triptans, Tramadol, St. John’s Wort): Increased risk of serotonin toxicity.
• CYP3A4 Substrates: Indalpine inhibits CYP3A4, potentially elevating plasma concentrations of co-administered CYP3A4-cleared drugs.

Indalpine, Food & Alcohol

Alcohol should be strictly avoided due to additive central nervous system depression and unpredictable alterations in mood and cognitive performance.

Indalpine: Missed Dose, Overdose & Storage

Dosing schedules are obsolete due to market withdrawal. Acute overdose induces severe serotonergic toxicity, hyperthermia, seizures, cardiac arrhythmias, and acute bone marrow depression, requiring immediate emergency medical evaluation, supportive resuscitation, and poison control consultation. Legacy chemical reference samples should be stored in tightly sealed containers at room temperature (15°C–30°C) protected from light and moisture.

Missed Dose of Indalpine

Because Indalpine is a withdrawn drug, standard missed dose schedules do not apply.

Indalpine Overdose & Emergency

Overdose of Indalpine can cause severe serotonergic toxicity, hyperthermia, seizures, cardiac arrhythmias, and acute bone marrow depression. In cases of acute accidental ingestion, seek immediate emergency medical care or contact a poison control center for supportive care.

How to Store Indalpine

Legacy or chemical reference samples should be stored in tightly sealed containers at controlled room temperature between 15°C and 30°C, protected from light and moisture, and kept strictly out of reach of children.

Indalpine Patient Management & Monitoring

Historical protocols required a baseline complete blood count (CBC) with differential, liver function tests, and renal panels prior to initiating therapy. Routine monitoring of white blood cell counts and clinical screening for fever, sore throat, or signs of infection were strictly required during treatment. Instruct anyone with suspected exposure to report high fever, sore throat, or unusual mouth sores immediately to evaluate for bone marrow failure.

Tests Before Starting Indalpine

• Baseline complete blood count (CBC) with differential to rule out pre-existing leukopenia or neutropenia.
• Baseline liver function tests and renal function panels.

Monitoring During Indalpine Treatment

Routine monitoring of white blood cell counts and clinical screening for fever, sore throat, or signs of infection was required during historical clinical use.

Indalpine Do’s and Don’ts

• Do seek immediate medical attention if experiencing fever or sore throat while exposed to legacy compounds.
• Do not purchase or ingest unapproved or legacy Indalpine products.
• Do not take alongside MAOIs or other serotonergic medications.

Frequently Asked Questions

References

• DrugBank Database – Indalpine Clinical and Pharmacological Profile (DB08953)
• Classyfire Database – 3-Alkylindoles Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex cardiovascular conditions, medication adjustments, or dietary changes.